Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis
- PMID: 18350160
- PMCID: PMC2265799
- DOI: 10.1371/journal.pone.0001824
Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis
Abstract
In vivo induced antigen technology (IVIAT) is an immuno-screening technique that identifies bacterial antigens expressed during infection and not during standard in vitro culturing conditions. We applied IVIAT to Bacillus anthracis and identified PagA, seven members of a N-acetylmuramoyl-L-alanine amidase autolysin family, three P60 family lipoproteins, two transporters, spore cortex lytic protein SleB, a penicillin binding protein, a putative prophage holin, respiratory nitrate reductase NarG, and three proteins of unknown function. Using quantitative real-time PCR comparing RNA isolated from in vitro cultured B. anthracis to RNA isolated from BALB/c mice infected with virulent Ames strain B. anthracis, we confirmed induced expression in vivo for a subset of B. anthracis genes identified by IVIAT, including L-alanine amidases BA3767, BA4073, and amiA (pXO2-42); the bacteriophage holin gene BA4074; and pagA (pXO1-110). The exogenous addition of two purified putative autolysins identified by IVIAT, N-acetylmuramoyl-L-alanine amidases BA0485 and BA2446, to vegetative B. anthracis cell suspensions induced a species-specific change in bacterial morphology and reduction in viable bacterial cells. Many of the proteins identified in our screen are predicted to affect peptidoglycan re-modeling, and our results support significant cell wall structural remodeling activity during B. anthracis infection. Identification of L-alanine amidases with B. anthracis specificity may suggest new potential therapeutic targets.
Conflict of interest statement
Figures
References
-
- Handfield M, Brady LJ, Progulske-Fox A, Hillman JD. IVIAT: a novel method to identify microbial genes expressed specifically during human infections. Trends Microbiol. 2000;8:336–339. - PubMed
-
- Rollins SM, Peppercorn A, Hang L, Hillman JD, Calderwood SB, et al. In vivo induced antigen technology (IVIAT). Cell Microbiol. 2005;7:1–9. - PubMed
-
- Handfield M, Hillman JD. In vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT). Infect Disord Drug Targets. 2006;6:327–334. - PubMed
-
- Deb DK, Dahiya P, Srivastava KK, Srivastava R, Srivastava BS. Selective identification of new therapeutic targets of Mycobacterium tuberculosis by IVIAT approach. Tuberculosis (Edinb ) 2002;82:175–182. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
